Literature DB >> 901736

Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.

G M Frigo, E Perucca, M Teggia-Droghi, G Gatti, A Mussini, J Salerno.   

Abstract

1 The time-course of quinidine plasma concentrations and selected kinetic parameters were studied in healthy male volunteers given single oral doses of four different quinidine formulations. Comparison was made with quinidine sulphate in a rapidly dissolving form. 2 Plasma half-lives did not significantly differ among treatments. 3 Quinidine polygalacturonate appears to be equivalent to quinidine sulphate in respect to both the absorption and elimination kinetics. When both quinidine bisulphate (Kinidin Durules) and quinidine arabogalactansulphate (Longacor) were administered plasma levels peaked significantly later than after quinidine sulphate. However, while the former seems to be absorbed to the same extent as quinidine sulphate, the latter exhibits lower bioavailability in respect to all other preparations.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 901736      PMCID: PMC1429058          DOI: 10.1111/j.1365-2125.1977.tb00760.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  QUANTITATIVE DETERMINATION OF QUINIDINE IN PLASMA.

Authors:  G CRAMER; B ISAKSSON
Journal:  Scand J Clin Lab Invest       Date:  1963       Impact factor: 1.713

2.  A new quinidine preparation with sustained release.

Authors:  G CRAMER; E VARNAUSKAS; L WERKO
Journal:  Acta Med Scand       Date:  1963-04

3.  Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration.

Authors:  R E BALL; M SOKOLOW
Journal:  Circulation       Date:  1956-10       Impact factor: 29.690

Review 4.  Individualization of dosage of antiarrhythmic drugs.

Authors:  K M Kessler
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

5.  [Comparative study of absorption and distribution of quinidine arabogalactane sulfate and quinidine sulfate].

Authors:  P Maurice; L Scebat; A Uzan
Journal:  Pathol Biol (Paris)       Date:  1974-02

6.  Serum quinidine levels after administration of three different quinidine preparations.

Authors:  R Henning; G Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

7.  Quinidine elimination in patients with congestive heart failure or poor renal function.

Authors:  K M Kessler; D T Lowenthal; H Warner; T Gibson; W Briggs; M M Reidenberg
Journal:  N Engl J Med       Date:  1974-03-28       Impact factor: 91.245

8.  Thin-layer chromatography for the quantitative separation of quinidine and quinidine metabolites from biological fluids and tissues.

Authors:  G Härtel; A Korhonen
Journal:  J Chromatogr       Date:  1968-09-24

Review 9.  Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  THE RELATIONSHIP OF DOSAGE SCHEDULE TO THE BLOOD LEVEL OF QUINIDINE, USING ALL AVAILABLE QUINIDINE PREPARATIONS.

Authors:  W M GOLDBERG; S G CHAKRABARTI
Journal:  Can Med Assoc J       Date:  1964-11-07       Impact factor: 8.262

View more
  6 in total

1.  Comparison of two long-acting forms of quinidine.

Authors:  A Leizorovicz; C Piolat; J P Boissel; B Sanchini; S Ferry
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

2.  Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods.

Authors:  T W Guentert; R A Upton; N H Holford; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

3.  Absorption of quinidine from an enteric-coated preparation.

Authors:  D Fremstad; O G Nilsen; J Amlie; L Storstein; B Olsson; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

4.  Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.

Authors:  Li Liu; Ann C Collier; Jeanne M Link; Karen B Domino; David A Mankoff; Janet F Eary; Charles F Spiekerman; Peng Hsiao; Anand K Deo; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2015-09-09       Impact factor: 3.922

Review 5.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  Quinidine dosage, with special reference to an oral loading dose schedule.

Authors:  P Collste; R Nordlander
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.